The efficacy and safety study of conventional therapy combined with lysozyme enteric-coated tablets for psoriasis

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000029848

Enrollment

Unknown

Registered

2020-02-15

Start date

2020-04-01

Completion date

Unknown

Last updated

2020-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis

Interventions

Experimental group:conventional therapy combined with lysozyme. Lysozyme enteric-coated tablets will be taken 1g each time with meal, twice a day for 12 weeks.

Control Group:conventional therapy combined with the placebo. Placebo tablets will be taken 1g each time with meal, twice a day for 12 weeks.

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Aged from 18 to 70 years, male and female; 2. Patients who has has been diagnosed with psoriasis and clearly classified; 3. Patients with a PASI score of no less than 5; 4. Patients who can communicate with researcher and sign informed consent form willingly; 5. Patients who showthe willingness to complete all steps and study intervention cycles in the study; 6. After instruction, patients who are able to fill out the patient diary card as required; 7. Patients who did not participate in any other clinical studies within three months.

Exclusion criteria

Exclusion criteria: 1. Patients whois allergic to egg whites and any components (including accessories) of the research drug; 2. Patients who have active inflammation of serious skin disease (e.g. malignant skin tumors) other than psoriasis; 3. Patients who is diagnosed with psoriasis vulgaris; 4. Patients with psoriasis caused by drugs such as calcium antagonistsor beta blockers; 5. Women who are pregnant or breast-feeding or recently planning pregnancy during the study; 6. Patients with infectious diseases (e.g. hiv, syphilis, infectious hepatitis, etc.); 7. Patients with serious illness or mental illness are considered unfit for study; 8. Patients with poor compliance or other conditions considered unsuitable for study by the researchers.

Design outcomes

Primary

Measure	Time frame
efficacy evaluation;	—

Secondary

Measure	Time frame
onset time; efficacy maintenance time ;Adverse events;	—

Countries

Chongqing

Contacts

Public ContactChangqing Lee

Guangzhou Century Clinical Research Co., Ltd.

lcq@welman.com.cn+86 13983396915

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026